- Open Access
Comparison of assessment techniques: plasma lipid and lipoproteins related to the metabolic syndrome
© Davy and Davy; licensee BioMed Central Ltd. 2006
- Received: 19 December 2005
- Accepted: 31 January 2006
- Published: 31 January 2006
The purpose of this investigation was to determine the influence of analytical method on reported concentrations of plasma lipids and lipoproteins, and to determine if there are clinical implications of any potential differences on identification of the metabolic syndrome dyslipidemia, CVD risk stratification and classification of LDL subclass phenotype.
Plasma triglyceride (TG) concentrations were 1.09 ± 0.06 and 1.17 ± 0.06 mmol/L and plasma high density lipoprotein cholesterol (HDL-C) concentrations were 1.09 ± 0.03 vs 1.19 ± 0.03 mmol/L (both p < 0.05) from 113 duplicate samples sent to two laboratories utilizing different lipid and lipoprotein analytical methods (LABS 1 and 2, respectively). Plasma total cholesterol and low-density lipoprotein cholesterol (LDL-C) concentrations were also significantly different between laboratories. Spearman rho correlations indicate excellent agreement of TG and HDL-C determined by the two laboratories (r = 0.96, TG; r = 0.91, HDL-C, both p < 0.001). Eleven vs. 14 individuals met the TG criteria and 70 vs. 48 met HDL-C metabolic syndrome criteria with LAB 1 and 2, respectively. Apoprotein B concentration (LAB 1) and LDL particle number (LAB 2) were highly correlated. (r = 0.92, P < 0.01). LAB 2 characterized more individuals as LDL pattern B phenotype, as compared to LAB 1 (30 vs. 14%, P < 0.05).
Different plasma lipid and lipoprotein analytical techniques yield results which are highly correlated, yet significantly different, which suggests a consistent measurement difference. This difference has clinical implications, in that the proportion of individuals identified as meeting the metabolic syndrome dyslipidemia criteria, "at risk" based upon apo B or LDL particle number, and the LDL pattern B phenotype will differ based upon choice of analytical method.
- Metabolic Syndrome
- High Density Lipoprotein Cholesterol
- Framingham Risk Score
- High Density Lipoprotein Cholesterol Concentration
- Plasma High Density Lipoprotein Cholesterol
The metabolic syndrome is a condition in which several abnormalities (hypertension, insulin resistance, dyslipidemia, and impaired fibrinolysis) are clustered together with elevated abdominal visceral fat as the central feature. Individuals with the metabolic syndrome, estimated to be approximately 24% of US adults, are at increased risk for developing diabetes and cardiovascular disease (CVD)[1–3]. One objective of the clinical management of the metabolic syndrome is the treatment of dyslipidemia, which is characterized by blood triglyceride (TG) concentrations above 1.69 mmol/L (150 mg/dl) and high-density lipoprotein cholesterol (HDL-C) concentrations below 1.03 mmol/L (40 mg/dl) in men and 1.29 mmol/L (50 mg/dl) in women .
The predominance of small, dense low-density lipoprotein (LDL) particles, termed LDL subclass pattern B phenotype, and apoprotein (apo) B concentration, which reflect the number of circulating atherogenic lipoprotein particles, have also been identified as important clinical markers of CVD risk [5, 6]. Importantly, the pattern B phenotype is associated with the metabolic syndrome . Small, dense LDL particles are cholesterol-depleted; therefore the use of total cholesterol (TC) and LDL-C concentrations may not reflect the number of circulating atherogenic particles in the plasma . For this reason, concentration of apo B (or LDL particle number, a closely related variable) may be useful in identifying and monitoring patients at risk for CVD . Furthermore, it has been suggested that apo B concentrations be used in place of traditional lipid parameters (TC, LDL-C, HDL-C, and triglycerides) to assess and monitor CVD risk [8–10]. Individuals with both the pattern B phenotype and a high apo B concentration have a six-fold increased risk of ischemic heart disease compared to those without these characteristics .
Various analytical methods are available for the determination of plasma lipid and lipoprotein concentrations and characteristics. Traditional methods include enzymatic method determination of TC, TG, and HDL-C and gradient gel electrophoresis (GGE)(LAB 1) for assessment of lipoprotein particle size and subclasses, while newer technology utilizes nuclear magnetic resonance (NMR) spectroscopy (LAB 2) for assessment of these variables . Both laboratories report similar coefficient of variations (CVs) of ~1–3% for lipid concentrations (TC, TG, HDL), while reported CVs for apo B (LAB 1) and LDL particle number (LAB 2) are ~6% and 2%, respectively [11, 12]. An advantage of the technique employed by LAB 1 is that it has been in use for longer period of time and is thus widely accepted, while an advantage of the newer NMR technique is that it is much less time- and labor-intensive. Other potential differences between analytical techniques include sample volume and cost. Analytical method may influence plasma lipid and lipoprotein concentrations and characteristics, and it is not clear if these potential differences have clinical implications (ie, identification of metabolic syndrome dyslipidemia or CVD risk stratification). Therefore, the purpose of this investigation was twofold: 1) to determine the influence of analytical method (LAB 1 vs. LAB 2) on reported concentrations of plasma lipids and lipoproteins, 2) to determine if there are clinical implications for these differences (ie, on clinical identification of the metabolic syndrome dyslipidemia, CVD risk stratification and classification of LDL subclass phenotype).
Plasma Lipid and Lipoprotein Concentrations from Laboratories Utilizing Different Analytical Methods
Total Cholesterol, mmol/L
4.13 ± 0.08
3.82 ± 0.08A
1.09 ± 0.03
1.19 ± 0.03A
2.53 ± 0.08
2.25 ± 0.05A
1.09 ± 0.06
1.17 ± 0.06A
Number in sample meeting ATP III criteria
Triglycerides, n (%)
HDL-C, n (%)
Various laboratories offer plasma lipid and lipoprotein assessment beyond the traditional lipid and lipoprotein panel, such as lipoprotein characteristics (eg, particle size) and number. These findings indicate that results may vary according to the analytical method used, and that this variability may have clinical implications for assessment of CVD risk. Results from the two laboratories studied in this investigation were significantly different; however, the measurement difference was consistent (eg, if an individual's reported TG value was elevated according to LAB 1, it was likely to be elevated according to LAB 2).
Individuals with the metabolic syndrome dyslipidemia risk determinants and with LDL subclass pattern B phenotype should be identified clinically, as they are at increased risk for CVD. However, the laboratory method used to analyze lipid and lipoprotein variables for CVD risk stratification and diagnosis of the metabolic syndrome dyslipidemia appears to impact the proportion of individuals identified to be "at-risk". Results from LAB 2 would categorize more individuals with the LDL pattern B phenotype, as well as at increased CVD risk based upon LDL particle number. Borderline results may warrant follow-up testing to ensure the appropriateness of risk categorization as well as the treatment approach employed.
Thus, lipid and lipoprotein results from the two laboratories studied were highly correlated (ie, r = 0.88–0.96), but differ significantly in their categorization of individuals at risk for CVD. These differences may lead to different clinical treatment strategies.
Duplicate fasting plasma samples were obtained from 113 (70 men, 43 women) participants of a cross-sectional research study. Participants were heterogeneous in terms of age (range 18–70 years), activity level (V02 max range 19.7–82.0 ml/kg/min), and body weight (BMI range 17.8–39.9). Participants were excluded if they had a history of cardiovascular disease, diabetes, or other major chronic disease. Physical characteristics (mean ± SEM) of participants were as follows: age 31.1 (± 1.2) years; height 173.6 (± 1.0) cm; weight 79.1 (± 1.4) kg; BMI 26.2 (± 0.4) kg/m2. All participants provided informed consent prior to their participation in the investigation.
Plasma samples were sent to two commercial laboratories specializing in plasma lipid and lipoprotein analyses. Both laboratories are CLIA-certified (Centers for Medicare and Medicaid Services Clinical Laboratory Improvement Amendments). One laboratory (LAB 1) utilizes enzymatic methods (TG, HDL-C, total cholesterol) plus gradient gel electrophoresis (particle size, subclasses) [13, 18] and the other laboratory (LAB 2) utilizes nuclear magnetic resonance spectroscopy . With regard to analysis of the number of circulating atherogenic particles, LAB 1 reports apo B concentrations (mg/dl), while LAB 2 reports LDL particle number (nmol/L). Concentrations of total cholesterol, TG, HDL-C, LDL-C, LDL particle number and apo B, and LDL subclass phenotype classification (Pattern A/B) were compared between laboratories. In addition, the proportion of individuals meeting ATP III dyslipidemia criteria according to results reported by the two laboratories was compared.
Spearman's rho rank order correlational analysis was used to assess agreement in ranking of variables between LABS 1 and 2, and paired samples t-tests were used to determine differences between laboratories. Chi square test of independence analysis was used to determine if the number of individuals classified as LDL pattern B phenotype and those meeting ATP III criteria for TG and HDL-C differed between laboratories (SPSS v. 12.0). Significance was determined as P < 0.05. All data are expressed as Mean ± SEM.
- Lorenzo C, Okoloise M, Williams K, Stern M, Haffner S: The metabolic syndrome as predictor of type 2 diabetes. Diab Care. 2003, 26: 3153-3159.View ArticleGoogle Scholar
- Malik S, Wong N, Franklin S, Kamath T, L'Italien G, Pio J, Williams R: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004, 110: 1245-1250. 10.1161/01.CIR.0000140677.20606.0EView ArticlePubMedGoogle Scholar
- Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults. JAMA. 2002, 287 (3): 356-359. 10.1001/jama.287.3.356View ArticlePubMedGoogle Scholar
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285 (19): 2486-2497.Google Scholar
- Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais G, Lupien P, Despres JP: Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation. 1997, 95: 69-75.View ArticlePubMedGoogle Scholar
- Kwiterovich P: HyperapoB: a pleiotropic phenotype characterized by dense low-density lipoproteins and associated with coronary artery disease. Clin Chem. 1988, 34 (8): B71-B77.PubMedGoogle Scholar
- Friedlander Y, Kidron M, Caslake M, Lamb T, McConnel M, Bar-On H: Low density lipoprotein particle size and risk factors of insulin resistance syndrome. Atherosclerosis. 2000, 148: 141-149. 10.1016/S0021-9150(99)00215-4View ArticlePubMedGoogle Scholar
- Miremadi S, Sniderman A, Frohlich J: Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?. Clin Chem. 2002, 48 (3): 484-488.PubMedGoogle Scholar
- Sniderman AD, Pedersen T, Kjekshus J: Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol. 1997, 79: 64-67. 10.1016/S0002-9149(96)00677-7View ArticlePubMedGoogle Scholar
- Demacker PNM, Veerkamp MJ, Bredit SJH, marcovina SM, de Graaf J, Stalenhoef AFH: Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia. Atherosclerosis. 2000, 153: 483-490. 10.1016/S0021-9150(00)00432-9View ArticlePubMedGoogle Scholar
- Otvos JD: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Handbook of Lipoprotein Testing. Edited by: Rifai N, Warnick G, Dominiczk M. 2000, 609-623. Washington, DC: American Association of Clinical Chemistry, 2Google Scholar
- Personal communication, Berkeley HeartLab, Inc.Google Scholar
- Berkeley HeartLabs, Inc. , http://www.bhlinc.com
- LipoScience, Inc. http://www.liposcience.com
- Blake GJ, Otvos JD, Rifai N, Ridker PM: Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002, 106: 1930-1937.View ArticlePubMedGoogle Scholar
- Haffner S, Williams K, Festa A, Hanley A: LDL particles, small LDL particles, and LDL size by nuclear magnetic resonance spectroscopy are more related to metabolic syndrome components than are apoB and LDL size by gradient gel electrophoresis [abstract]. American Diabetes Association. 2005, http://scientificsessions.diabetes.org/AbstractsGoogle Scholar
- Krauss R: Atherogenic lipoprotein phenotype and diet-gene interactions. J Nutr. 2001, 131: 340S-343S.PubMedGoogle Scholar
- Krauss RM, Burke DJ: Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 1982, 23: 97-104.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.